FDA reviewers endorse Medicines' cangrelor; back to CRDAC
This article was originally published in Scrip
Executive Summary
After getting smacked down last year, the Medicines Company (MDCO) is headed back to the FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) on 15 April with its antiplatelet agent cangrelor for a second round.